To appraise the clinical and cost-effectiveness of Mirvetuximab soravtansine within its marketing authorisation ovarian cancer, peritoneal cancer, or fallopian tube cancer
Status In progress
Process STA 2018
ID number 1527


Key events during the development of the guidance:

Date Update
20 May 2019 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
02 May 2019 In progress. Referred on 27 June 2018

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance